Homer L Twigg1, Kenneth S Knox2, Jin Zhou2, Kristina A Crothers3, David E Nelson4, Evelyn Toh4, Richard B Day1, Huaiying Lin5, Xiang Gao5, Qunfeng Dong5, Deming Mi6, Barry P Katz6, Erica Sodergren7, George M Weinstock7. 1. 1 Department of Medicine. 2. 2 Department of Medicine, University of Arizona, Tucson, Arizona. 3. 3 Department of Medicine, University of Washington, Seattle, Washington. 4. 4 Department of Microbiology and Immunology, and. 5. 5 Center for Biomedical Informatics, Department of Public Health Sciences, Loyola University Chicago, Maywood, Illinois; and. 6. 6 Department of Biostatistics, Indiana University, Indianapolis, Indiana. 7. 7 Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Abstract
RATIONALE: Previous work found the lung microbiome in healthy subjects infected with HIV was similar to that in uninfected subjects. We hypothesized the lung microbiome from subjects infected with HIV with more advanced disease would differ from that of an uninfected control population. OBJECTIVES: To measure the lung microbiome in an HIV-infected population with advanced disease. METHODS: 16s RNA gene sequencing was performed on acellular bronchoalveolar lavage (BAL) fluid from 30 subjects infected with HIV with advanced disease (baseline mean CD4 count, 262 cells/mm(3)) before and up to 3 years after starting highly active antiretroviral therapy (HAART) and compared with 22 uninfected control subjects. MEASUREMENTS AND MAIN RESULTS: The lung microbiome in subjects infected with HIV with advanced disease demonstrated decreased alpha diversity (richness and diversity) and greater beta diversity compared with uninfected BAL. Differences improved with HAART, but still persisted up to 3 years after starting therapy. Population dispersion in the group infected with HIV was significantly greater than in the uninfected cohort and declined after treatment. There were differences in the relative abundance of some bacteria between the two groups at baseline and after 1 year of therapy. After 1 year on HAART, HIV BAL contained an increased abundance of Prevotella and Veillonella, bacteria previously associated with lung inflammation. CONCLUSIONS: The lung microbiome in subjects infected with HIV with advanced disease is altered compared with an uninfected population both in diversity and bacterial composition. Differences remain up to 3 years after starting HAART. We speculate an altered lung microbiome in HIV infection may contribute to chronic inflammation and lung complications seen in the HAART era.
RATIONALE: Previous work found the lung microbiome in healthy subjects infected with HIV was similar to that in uninfected subjects. We hypothesized the lung microbiome from subjects infected with HIV with more advanced disease would differ from that of an uninfected control population. OBJECTIVES: To measure the lung microbiome in an HIV-infected population with advanced disease. METHODS: 16s RNA gene sequencing was performed on acellular bronchoalveolar lavage (BAL) fluid from 30 subjects infected with HIV with advanced disease (baseline mean CD4 count, 262 cells/mm(3)) before and up to 3 years after starting highly active antiretroviral therapy (HAART) and compared with 22 uninfected control subjects. MEASUREMENTS AND MAIN RESULTS: The lung microbiome in subjects infected with HIV with advanced disease demonstrated decreased alpha diversity (richness and diversity) and greater beta diversity compared with uninfected BAL. Differences improved with HAART, but still persisted up to 3 years after starting therapy. Population dispersion in the group infected with HIV was significantly greater than in the uninfected cohort and declined after treatment. There were differences in the relative abundance of some bacteria between the two groups at baseline and after 1 year of therapy. After 1 year on HAART, HIV BAL contained an increased abundance of Prevotella and Veillonella, bacteria previously associated with lung inflammation. CONCLUSIONS: The lung microbiome in subjects infected with HIV with advanced disease is altered compared with an uninfected population both in diversity and bacterial composition. Differences remain up to 3 years after starting HAART. We speculate an altered lung microbiome in HIV infection may contribute to chronic inflammation and lung complications seen in the HAART era.
Entities:
Keywords:
HIV infection; advanced disease; lung microbiome; microbial diversity
Authors: Hadas Hawlena; Evelyn Rynkiewicz; Evelyn Toh; Andrew Alfred; Lance A Durden; Michael W Hastriter; David E Nelson; Ruichen Rong; Daniel Munro; Qunfeng Dong; Clay Fuqua; Keith Clay Journal: ISME J Date: 2012-06-28 Impact factor: 10.302
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Leopoldo N Segal; Alexander V Alekseyenko; Jose C Clemente; Rohan Kulkarni; Benjamin Wu; Zhan Gao; Hao Chen; Kenneth I Berger; Roberta M Goldring; William N Rom; Martin J Blaser; Michael D Weiden Journal: Microbiome Date: 2013-07-01 Impact factor: 14.650
Authors: Homer L Twigg; Ronald Crystal; Judith Currier; Paul Ridker; Nancy Berliner; Hans-Peter Kiem; George Rutherford; Shimian Zou; Simone Glynn; Renee Wong; Emmanuel Peprah; Michael Engelgau; Tony Creazzo; Sandra Colombini-Hatch; Elisabet Caler Journal: AIDS Res Hum Retroviruses Date: 2017-06-26 Impact factor: 2.205
Authors: Rachel M Presti; Sonia C Flores; Brent E Palmer; Jeffrey J Atkinson; Catherine R Lesko; Bryan Lau; Andrew P Fontenot; Jesse Roman; John F McDyer; Homer L Twigg Journal: Chest Date: 2017-04-17 Impact factor: 9.410
Authors: Derrick R Samuelson; Ellen L Burnham; Vincent J Maffei; R William Vandivier; Eugene E Blanchard; Judd E Shellito; Meng Luo; Christopher M Taylor; David A Welsh Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-08-31 Impact factor: 5.464
Authors: Meera K Shenoy; Shoko Iwai; Din L Lin; William Worodria; Irene Ayakaka; Patrick Byanyima; Sylvia Kaswabuli; Serena Fong; Stephen Stone; Emily Chang; J Lucian Davis; Ali Ahmad Faruqi; Mark R Segal; Laurence Huang; Susan V Lynch Journal: Am J Respir Crit Care Med Date: 2017-01-01 Impact factor: 21.405